Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. reports developments in sleep health, respiratory care and home healthcare technology. The company supplies sleep apnea and breathing-care devices, including CPAP platforms such as AirSense 11, and supports them with cloud-connected software, AI-enabled digital health tools and patient data applications used in out-of-hospital care.
Recurring updates include quarterly operating results, demand trends for sleep and respiratory care products, FDA-cleared digital medical devices such as Smart Comfort, supply-chain and distribution capacity, shareholder returns, executive leadership changes and investor conference presentations. ResMed’s announcements also reflect its NYSE-listed common stock and ASX-traded presence.
ResMed reported a strong performance for the second quarter of 2021, with a 9% increase in revenue to $800.0 million. Net operating profit rose 12%, and GAAP diluted EPS grew to $1.23. These results were supported by growth in core markets like sleep apnea and COPD despite a 20 basis point contraction in gross margin due to restructuring expenses. Notably, non-GAAP EPS improved by 17%. The company also declared a quarterly cash dividend of $0.39 per share, demonstrating financial strength as it aims to enhance digital health solutions.
ResMed (NYSE: RMD, ASX: RMD) will release its financial and operational results for Q2 of fiscal 2021 on January 28, 2021, post-market close. A webcast is scheduled to follow, where management will discuss results and potentially other forward-looking information.
The earnings webcast will take place at 1:30 p.m. PST / 4:30 p.m. EST, with international times provided for London and Sydney. A replay will be available on ResMed’s website within two hours of the event and will also feature a phone replay option available until February 11.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at approximately 4:30 PM EST via webcast. The conference will provide insights into ResMed's innovative digital health technologies and cloud-connected medical devices, aimed at treating chronic diseases like sleep apnea and COPD. The audio-only webcast replay will be available about an hour after the presentation and remain accessible for 30 days.
ResMed has launched a new sleep education campaign, #WakeUpToGoodSleep, aimed at raising awareness of sleep disorders in India, where over one million people suffer from sleep apnea. The campaign emphasizes the critical impact of sleep quality on overall well-being, with untreated sleep disorders linked to health issues like diabetes and heart attacks. It also features a sleep coach assistant service to guide patients through sleep apnea detection and treatment options. Since May 2020, ResMed has trained over 700 doctors in sleep health education to enhance public awareness.
ResMed (NYSE: RMD) has announced that CEO Mick Farrell will participate in a virtual fireside chat at the Credit Suisse 29th Annual Global Healthcare Conference on November 10, 2020, at 5:00 p.m. EST. This event will be available via video webcast. More details and access to the live webcast can be found at investor.resmed.com. A replay will be accessible about an hour after the live event, remaining available until November 10, 2021.
ResMed (NYSE: RMD) plans to report its financial and operational results for Q1 FY 2021 on October 29, 2020, after market close. A management webcast will follow to discuss these results and additional forward-looking information. The earnings call is scheduled for 1:30 p.m. PDT / 4:30 p.m. EDT and will be accessible through ResMed's investor relations website.
The earnings call replay will be available for two weeks following the event. ResMed specializes in innovative health solutions for chronic diseases, enhancing care quality while reducing healthcare costs globally.
VIDA Diagnostics has appointed Karen Drexler to its board of directors, enhancing its leadership in digital health technology amid the ongoing COVID-19 pandemic. Drexler, an experienced entrepreneur with a background in digital health and established accolades, aims to support VIDA's mission to modernize lung and respiratory care. Her appointment is expected to bolster market expansion and innovation in AI-powered lung intelligence solutions, aligning with the heightened focus on lung health and the rising demand for advanced medical technologies.